Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.

doi:10.1200/JCO.21.01612

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2022

Pollard Jessica A, Alonzo Todd A, Gerbing Robert, Brown Patrick, Fox Elizabeth, Choi John, Fisher Brian, Hirsch Betsy, Kahwash Samir, Getz Kelly, Levine John, Brodersen Lisa Eidenschink, Loken Michael R, Raimondi Susana, Tarlock Katherine, Wood Andrew, Sung Lillian, Kolb E Anders, Gamis Alan, Meshinchi Soheil, Aplenc Richard

Abstract excerpt

PURPOSE: High allelic ratio (HAR) FLT3/ITD (AR > 0.4) mutations confer poor prognosis in pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and efficacy of adding sorafenib, a multikinase tyrosine kinase inhibitor to standard chemotherapy and as single-agent maintenance therapy in this population. MATERIALS AND METHODS: Patients were treated in three cohorts. The initial safety phase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Phenylurea Compounds

Share to Protein Kinase Inhibitors

Share to Remission Induction

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35349331
DOI: 10.1200/JCO.21.01612
PMCID: PMC9197362

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.PMID 35349331Read ↗

Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibSemantic proximity Read ↗

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.Semantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.Semantic proximity Read ↗

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Semantic proximity Read ↗

Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.Semantic proximity Read ↗

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.Semantic proximity Read ↗

[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.Semantic proximity Read ↗

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.